Research programme: submicron cancer therapeutics - iCeutica

Drug Profile

Research programme: submicron cancer therapeutics - iCeutica

Alternative Names: ICE-1207; ICE-1208

Latest Information Update: 01 Oct 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator iCeutica
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Non-small cell lung cancer; Pancreatic cancer

Most Recent Events

  • 29 Sep 2014 Research programme: submicron cancer therapeutics - iCeutica is available for licensing as of 29 Sep 2014. http://www.iceutica.com/
  • 29 Sep 2014 Preclinical trials in Acute myeloid leukaemia in USA (PO)
  • 29 Sep 2014 Preclinical trials in Non-small cell lung cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top